Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia 12 15 74
Lobular Carcinoma in Situ of Breast 74
Non-Infiltrating Lobular Carcinoma 74
Lobular Intraepithelial Neoplasia 12
Lobular Carcinoma in Situ 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3010
NCIt 51 C27939
ICD10 34 D05.0

Summaries for Lobular Neoplasia

Disease Ontology : 12 A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary : Lobular Neoplasia, also known as lobular carcinoma in situ of breast, is related to in situ carcinoma and ductal carcinoma in situ. An important gene associated with Lobular Neoplasia is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Docetaxel and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast and bone, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : 77 Lobular neoplasia can refer... more...

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 in situ carcinoma 30.5 CDH1 ERBB2 ESR1
2 ductal carcinoma in situ 29.7 CDH1 ERBB2 ESR1 MUC1
3 breast disease 29.4 ERBB2 ESR1 ESR2 PRLR
4 breast cancer 28.4 CDH1 CTNNB1 ERBB2 ESR1 ESR2 MUC1
5 vaginitis 10.4 ESR1 ESR2
6 large intestine adenocarcinoma 10.3 CDH1 CTNNB1
7 progesterone resistance 10.3 ESR1 ESR2
8 goblet cell carcinoid 10.3 CDH1 CTNNB1
9 gender identity disorder 10.3 ESR1 ESR2
10 breast fibroadenoma 10.3
11 estrogen excess 10.3 ESR1 ESR2
12 dental fluorosis 10.3 ESR1 ESR2
13 female reproductive endometrioid cancer 10.3 CTNNB1 ESR1
14 endometriosis of ovary 10.3 ESR1 ESR2
15 benign breast phyllodes tumor 10.2
16 gastric diffuse adenocarcinoma 10.2 CDH1 CTNNA1
17 tongue disease 10.2 CDH1 CTNNB1
18 biphasic synovial sarcoma 10.2 CDH1 MUC1
19 endometrial mucinous adenocarcinoma 10.1 ESR1 MUC1
20 colonic disease 10.1 CDH1 CTNNB1 ESR1
21 sarcomatoid renal cell carcinoma 10.1 CDH1 MUC1
22 male reproductive organ cancer 10.1 CDH1 CTNNB1 ESR2
23 syringoma 10.1 ESR1 MUC1
24 postmenopausal atrophic vaginitis 10.1 ESR1 ESR2 PRLR
25 lymphoepithelioma-like carcinoma 10.1 CDH1 MUC1
26 adenomyoma 10.1 CTNNB1 MUC1
27 colon adenocarcinoma 10.1 CDH1 CTNNB1 ESR2
28 tongue cancer 10.1 CDH1 CTNNB1 PRLR
29 chondroid chordoma 10.1 CDH1 MUC1
30 sulfite oxidase deficiency due to molybdenum cofactor deficiency 10.1
31 gastric cardia carcinoma 10.1 CDH1 MUC1
32 peritoneal mesothelioma 10.1 ESR1 MUC1
33 sclerosing hemangioma 10.1 CTNNB1 MUC1
34 breast cystic hypersecretory carcinoma 10.1 CDH1 ERBB2
35 glassy cell carcinoma of the cervix 10.1 ERBB2 ESR1
36 breast medullary carcinoma 10.0 ERBB2 ESR1
37 comedo carcinoma 10.0 ERBB2 ESR1
38 breast adenoid cystic carcinoma 10.0 ERBB2 ESR1
39 signet ring cell adenocarcinoma 10.0 CDH1 MUC1
40 diffuse gastric cancer 10.0 CDH1 CTNNA1
41 polymorphous low-grade adenocarcinoma 10.0 CTNNB1 MUC1
42 epstein-barr virus-associated gastric carcinoma 10.0 CDH1 CTNNB1
43 luminal breast carcinoma 10.0 ERBB2 ESR1
44 breast benign neoplasm 10.0 ERBB2 ESR1
45 thoracic benign neoplasm 10.0 ERBB2 ESR1
46 uterine corpus cancer 10.0 ERBB2 ESR1
47 sarcoma, synovial 10.0 CDH1 CTNNB1 MUC1
48 intrahepatic cholangiocarcinoma 10.0 CDH1 CTNNB1 MUC1
49 hidradenocarcinoma 9.9 ERBB2 ESR1
50 bile duct adenocarcinoma 9.9 CDH1 MUC1

Graphical network of the top 20 diseases related to Lobular Neoplasia:



Diseases related to Lobular Neoplasia

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 CASK CTNNA1 CTNNB1 MUC1
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.92 CTNNA1 CTNNB1 ERBB2 MUC1

MGI Mouse Phenotypes related to Lobular Neoplasia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
2 growth/size/body region MP:0005378 10.11 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
3 behavior/neurological MP:0005386 10.09 CASK CTNNB1 ERBB2 ESR1 ESR2 HSP90AA1
4 endocrine/exocrine gland MP:0005379 10.08 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
5 integument MP:0010771 10.03 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
6 digestive/alimentary MP:0005381 9.99 CASK CDH1 CTNNB1 ERBB2 ESR1 ESR2
7 embryo MP:0005380 9.97 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 PRLR
8 mortality/aging MP:0010768 9.97 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
9 limbs/digits/tail MP:0005371 9.95 CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
10 craniofacial MP:0005382 9.92 CASK CTNNA1 CTNNB1 ERBB2 HSP90AA1
11 neoplasm MP:0002006 9.87 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
12 nervous system MP:0003631 9.8 CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
13 reproductive system MP:0005389 9.76 CASK CDH1 CTNNB1 ERBB2 ESR1 ESR2
14 respiratory system MP:0005388 9.35 CASK CTNNB1 ERBB2 ESR1 ESR2
15 skeleton MP:0005390 9.17 CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 4,Phase 2,Phase 3 114977-28-5 148124
2
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 6055-19-2, 50-18-0 2907
4 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
5 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
6 Immunologic Factors Phase 4,Phase 3,Phase 2
7 Antimitotic Agents Phase 4,Phase 3,Phase 2
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
9 Alkylating Agents Phase 4,Phase 3,Phase 2
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
12 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
13
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
14
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3 180288-69-1 9903
15
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
16
Tamoxifen Approved Phase 3,Phase 2,Not Applicable 10540-29-1 2733526
17
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Not Applicable 68-04-2
18
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
19
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
20
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
21
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
22
Letrozole Approved, Investigational Phase 3,Phase 1 112809-51-5 3902
23
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
24
Progesterone Approved, Vet_approved Phase 3,Not Applicable 57-83-0 5994
25
Metformin Approved Phase 3 657-24-9 14219 4091
26
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
27
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
28
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
29
Carboplatin Approved Phase 3 41575-94-4 38904 10339178 498142
30
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 77-92-9 311
31
Doxil Approved June 1999 Phase 3,Phase 2 31703
32
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
33 Antimetabolites, Antineoplastic Phase 3,Phase 2
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
36 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3
37 Contraceptive Agents Phase 3
38 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
39 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
40 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
41 Citrate Phase 3,Phase 2,Not Applicable
42
Medroxyprogesterone Phase 3 520-85-4 10631
43 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
44 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
45 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
49 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Contraceptives, Oral Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
2 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
3 Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Completed NCT00336791 Phase 3 5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
4 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
5 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Completed NCT00083174 Phase 3 exemestane
6 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
7 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
8 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
9 A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin Recruiting NCT03085368 Phase 2, Phase 3 lapatinib/herceptin
10 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
11 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
12 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
13 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
14 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
15 The LightPath® and 68Ga-RM2 in Breast Cancer Study Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
16 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
17 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
18 Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. Completed NCT00524303 Phase 2 Trastuzumab;Paclitaxel;FEC75;Lapatinib
19 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
20 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
21 A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. Completed NCT00717405 Phase 2 Standard chemotherapy;bevacizumab [Avastin];trastuzumab [Herceptin]
22 Ruxolitinib for Premalignant Breast Disease Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
23 Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Active, not recruiting NCT02137252 Phase 2 Naltrexone;Sugar Pill
24 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Active, not recruiting NCT01556243 Phase 2
25 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Active, not recruiting NCT02314156 Phase 2 Telapristone Acetate;Telapristone Acetate
26 3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer Active, not recruiting NCT03391388 Phase 2
27 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery Active, not recruiting NCT01082211 Phase 2
28 Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery Active, not recruiting NCT00436566 Phase 2 cyclophosphamide;doxorubicin hydrochloride;lapatinib ditosylate;paclitaxel
29 Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer Terminated NCT00096369 Phase 2 tamoxifen citrate
30 S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women Terminated NCT00088972 Phase 2 celecoxib
31 Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery Terminated NCT01754519 Phase 2
32 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial Completed NCT01372644 Phase 1 SOM 230 / Pasireotide
33 Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer Completed NCT01077453 Phase 1 letrozole
34 A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Completed NCT00637481 Phase 1 atorvastatin calcium
35 Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer Completed NCT00245024 Phase 1 sulindac
36 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer Recruiting NCT03323658 Phase 1 Bexarotene
37 Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Suspended NCT03317405 Phase 1 Z-Endoxifen Hydrochloride
38 Genetics of Women With Lobular Carcinoma in Situ of the Breast Unknown status NCT00536718
39 Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy Completed NCT00146536
40 Molecular Breast Imaging in Women With Atypia and LCIS Completed NCT00620087 Not Applicable
41 Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast Completed NCT01841749 Not Applicable
42 S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Completed NCT01097278 Not Applicable
43 Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer Completed NCT01874184 Not Applicable
44 Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer Completed NCT00666731
45 Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed NCT01293032 Not Applicable Systemic Chemotherapy;Tamoxifen Citrate;Aromatase Inhibition Therapy
46 Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients Completed NCT01723943 Not Applicable
47 Three Different Programs of Paced Breathing in Treating Hot Flashes in Women Completed NCT00569166 Not Applicable
48 Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer Completed NCT00937989 Not Applicable
49 Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer Completed NCT00084669 Not Applicable venlafaxine;zolpidem tartrate
50 High-Risk Breast Duct Epithelium Recruiting NCT00028340

Search NIH Clinical Center for Lobular Neoplasia

Genetic Tests for Lobular Neoplasia

Anatomical Context for Lobular Neoplasia

MalaCards organs/tissues related to Lobular Neoplasia:

42
Breast, Bone

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 93)
# Title Authors Year
1
Supplemental ultrasound screening in patients with a history of lobular neoplasia. ( 30675929 )
2019
2
Observation versus excision of lobular neoplasia on core needle biopsy of the breast. ( 29299726 )
2018
3
Sonographic Appearance of Lesions Diagnosed as Lobular Neoplasia at Sonographically Guided Biopsies. ( 28075608 )
2017
4
Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy? ( 28118035 )
2017
5
Lobular Neoplasia and Atypical Ductal Hyperplasia on Core Biopsy: Current Surgical Management Recommendations. ( 28766203 )
2017
6
Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. ( 27806840 )
2016
7
When pathological and radiological correlation is achieved, excision of fibroadenoma with lobular neoplasia on core biopsy is not warranted. ( 27718416 )
2016
8
Lobular Neoplasia: Another Reset in Management? ( 26676981 )
2016
9
Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study ofA 316 Cases. ( 27425222 )
2016
10
Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. ( 26564004 )
2016
11
The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. ( 27060553 )
2016
12
CD10-positive myoepithelial cells are usually prominent around in situ lobular neoplasia of the breast and much less prominent or absent in DCIS. ( 26862059 )
2016
13
Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). ( 26542585 )
2015
14
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. ( 24441664 )
2014
15
Lobular neoplasia: morphology and management. ( 25268198 )
2014
16
Mucinous breast carcinoma with a lobular neoplasia component: a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation. ( 24888775 )
2014
17
Lobular neoplasia. ( 24882347 )
2014
18
Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. ( 24948027 )
2014
19
Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. ( 24633840 )
2014
20
Lobular neoplasia: what does it mean and how should it be treated? ( 23617527 )
2013
21
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. ( 23759937 )
2013
22
Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy. ( 23307062 )
2013
23
Low frequency of cancer occurrence in same breast quadrant diagnosed with lobular neoplasia at percutaneous needle biopsy. ( 22344406 )
2012
24
Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. ( 21953071 )
2012
25
Cadherin-catenin complex dissociation in lobular neoplasia of the breast. ( 22080244 )
2012
26
Lobular lesions of the breast: imaging findings of lobular neoplasia and invasive lobular carcinoma. ( 22324264 )
2012
27
Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. ( 22847124 )
2012
28
Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? ( 22997389 )
2012
29
Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. ( 22706860 )
2012
30
Breast-specific gamma imaging in the detection of atypical ductal hyperplasia and lobular neoplasia. ( 22578225 )
2012
31
Surgical outcome of biopsy-proven lobular neoplasia: is there any difference between lobular carcinoma in situ and atypical lobular hyperplasia? ( 22268170 )
2012
32
Lobular neoplasia: frequency and association with other breast lesions. ( 21827679 )
2011
33
Amplification of the prolactin receptor gene in mammary lobular neoplasia. ( 20658264 )
2011
34
In situ lobular neoplasia of the breast with marked myoepithelial proliferation. ( 21707709 )
2011
35
Lobular neoplasia found on breast biopsy: marker of increased risk of malignancy or direct pre-cancerous lesion? ( 22038220 )
2011
36
Lobular neoplasia: how to manage with partial understanding. ( 22106558 )
2011
37
Management of in situ lobular neoplasia detected on needle core biopsy of breast. ( 20972243 )
2010
38
Lobular neoplasia: morphology, biological potential and management in core biopsies. ( 20436498 )
2010
39
Lobular neoplasia displaying central necrosis: a potential diagnostic pitfall. ( 20359832 )
2010
40
Lobular neoplasia of the breast. ( 20701604 )
2010
41
Lobular neoplasia: evolution of its significance and morphologic spectrum. ( 20484286 )
2010
42
Lobular neoplasia of the breast: 68 years on. ( 19089737 )
2009
43
Lobular neoplasia of the breast: an update. ( 19642738 )
2009
44
Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. ( 19294736 )
2009
45
Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. ( 19170233 )
2009
46
Is excisional biopsy indicated for patients with lobular neoplasia diagnosed on percutaneous core needle biopsy of the breast? ( 19969131 )
2009
47
Sampling lobular neoplasia of the breast: underestimation despite technical success? ( 19466452 )
2009
48
Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. ( 18619840 )
2008
49
In situ and invasive lobular neoplasia of the breast. ( 18171417 )
2008
50
Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. ( 18287433 )
2008

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

9 (show top 50) (show all 1435)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6949530 ZRSR2 breast,NS,carcinoma,lobular carcinoma c.772-1G>C p.? 23:15818586-15818586 0
2 COSM6958693 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.7262C>G p.S2421* 16:72795420-72795420 0
3 COSM5037959 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4556C>G p.S1519* 16:72798126-72798126 0
4 COSM6953298 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.9220C>T p.Q3074* 16:72793462-72793462 0
5 COSM6906826 YES1 breast,NS,carcinoma,lobular carcinoma c.1090G>C p.D364H 18:739782-739782 0
6 COSM6921648 YAP1 breast,NS,carcinoma,lobular carcinoma c.952C>T p.Q318* 11:102223703-102223703 0
7 COSM3839782 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 0
8 COSM6923776 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 0
9 COSM6953971 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 0
10 COSM638 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 0
11 COSM637 WNK1 breast,NS,carcinoma,lobular carcinoma c.6569C>G p.S2190C 12:900596-900596 0
12 COSM18026 VHL breast,NS,carcinoma,lobular carcinoma c.562C>G p.L188V 3:10149885-10149885 0
13 COSM17721 VHL breast,NS,carcinoma,lobular carcinoma c.241C>T p.P81S 3:10142088-10142088 0
14 COSM51319 USP28 breast,NS,carcinoma,lobular carcinoma c.2050G>A p.D684N 11:113809177-113809177 0
15 COSM6963846 TSHR breast,NS,carcinoma,lobular carcinoma c.1283C>T p.A428V 14:81143341-81143341 0
16 COSM6911141 TSC2 breast,NS,carcinoma,lobular carcinoma c.700G>A p.E234K 16:2056695-2056695 0
17 COSM6929739 TSC2 breast,NS,carcinoma,lobular carcinoma c.3042C>G p.S1014R 16:2079107-2079107 0
18 COSM6909235 TSC2 breast,NS,carcinoma,lobular carcinoma c.1615C>T p.L539F 16:2065534-2065534 0
19 COSM6971312 TSC2 breast,NS,carcinoma,lobular carcinoma c.429C>G p.F143L 16:2054388-2054388 0
20 COSM6958690 TSC2 breast,NS,carcinoma,lobular carcinoma c.3887C>G p.S1296C 16:2083698-2083698 0
21 COSM6971309 TSC1 breast,NS,carcinoma,lobular carcinoma c.3208G>A p.A1070T 9:132896522-132896522 0
22 COSM6188 TRIM33 breast,NS,carcinoma,lobular carcinoma c.2968-1G>C p.? 1:114399610-114399610 0
23 COSM6971833 TRAF7 breast,NS,carcinoma,lobular carcinoma c.104G>A p.G35E 16:2165901-2165901 0
24 COSM3408510 TP63 breast,NS,carcinoma,lobular carcinoma c.679G>A p.A227T 3:189864331-189864331 0
25 COSM6940226 TP63 breast,NS,carcinoma,lobular carcinoma c.1865G>T p.S622I 3:189894324-189894324 0
26 COSM6958680 TP63 breast,NS,carcinoma,lobular carcinoma c.1079G>C p.R360T 3:189868666-189868666 0
27 COSM6926297 TP63 breast,NS,carcinoma,lobular carcinoma c.1432G>C p.V478L 3:189886476-189886476 0
28 COSM10768 TP53 breast,NS,carcinoma,lobular carcinoma c.535C>T p.H179Y 17:7675077-7675077 0
29 COSM43878 TP53 breast,NS,carcinoma,lobular carcinoma c.427G>A p.V143M 17:7675185-7675185 0
30 COSM43606 TP53 breast,NS,carcinoma,lobular carcinoma c.734G>A p.G245D 17:7674229-7674229 0
31 COSM10656 TP53 breast,NS,carcinoma,lobular carcinoma c.742C>T p.R248W 17:7674221-7674221 0
32 COSM10812 TP53 breast,NS,carcinoma,lobular carcinoma c.722C>T p.S241F 17:7674241-7674241 0
33 COSM44599 TP53 breast,NS,carcinoma,lobular carcinoma c.587G>A p.R196Q 17:7674944-7674944 0
34 COSM10719 TP53 breast,NS,carcinoma,lobular carcinoma c.811G>A p.E271K 17:7673809-7673809 0
35 COSM10733 TP53 breast,NS,carcinoma,lobular carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
36 COSM11073 TP53 breast,NS,carcinoma,lobular carcinoma c.1024C>T p.R342* 17:7670685-7670685 0
37 COSM44169 TP53 breast,NS,carcinoma,lobular carcinoma c.614A>C p.Y205S 17:7674917-7674917 0
38 COSM43695 TP53 breast,NS,carcinoma,lobular carcinoma c.748C>T p.P250S 17:7674215-7674215 0
39 COSM11552 TP53 breast,NS,carcinoma,lobular carcinoma c.775G>T p.D259Y 17:7674188-7674188 0
40 COSM44268 TP53 breast,NS,carcinoma,lobular carcinoma c.559+1G>T p.? 17:7675052-7675052 0
41 COSM10654 TP53 breast,NS,carcinoma,lobular carcinoma c.637C>T p.R213* 17:7674894-7674894 0
42 COSM10648 TP53 breast,NS,carcinoma,lobular carcinoma c.524G>A p.R175H 17:7675088-7675088 0
43 COSM46103 TP53 breast,NS,carcinoma,lobular carcinoma c.319T>G p.Y107D 17:7676050-7676050 0
44 COSM10722 TP53 breast,NS,carcinoma,lobular carcinoma c.853G>A p.E285K 17:7673767-7673767 0
45 COSM10728 TP53 breast,NS,carcinoma,lobular carcinoma c.839G>A p.R280K 17:7673781-7673781 0
46 COSM11059 TP53 breast,NS,carcinoma,lobular carcinoma c.713G>A p.C238Y 17:7674250-7674250 0
47 COSM10704 TP53 breast,NS,carcinoma,lobular carcinoma c.844C>T p.R282W 17:7673776-7673776 0
48 COSM10726 TP53 breast,NS,carcinoma,lobular carcinoma c.856G>A p.E286K 17:7673764-7673764 0
49 COSM10867 TP53 breast,NS,carcinoma,lobular carcinoma c.797G>A p.G266E 17:7673823-7673823 0
50 COSM43597 TP53 breast,NS,carcinoma,lobular carcinoma c.538G>T p.E180* 17:7675074-7675074 0

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
2
Show member pathways
13.06 CDH1 CTNNB1 ERBB2 ESR1 ESR2 HSP90AA1
3
Show member pathways
12.82 CTNNB1 ERBB2 HSP90AA1 PRLR
4
Show member pathways
12.75 CASK CDH1 CTNNA1 CTNNB1
5
Show member pathways
12.65 CDH1 CTNNA1 CTNNB1 ERBB2 HSP90AA1
6
Show member pathways
12.5 CASK CDH1 CTNNA1 CTNNB1
7
Show member pathways
12.49 CDH1 ERBB2 ESR1 ESR2
8
Show member pathways
12.46 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
9
Show member pathways
12.31 ERBB2 ESR1 ESR2 PRLR
10
Show member pathways
12.25 CTNNB1 ESR1 HSP90AA1
11
Show member pathways
12.21 CDH1 CTNNA1 CTNNB1 ERBB2
12
Show member pathways
12.17 ERBB2 ESR1 ESR2
13 12.14 CTNNB1 ERBB2 ESR1
14
Show member pathways
12.1 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
15
Show member pathways
12.05 CTNNA1 CTNNB1 HSP90AA1
16 12 CDH1 CTNNA1 CTNNB1
17 11.99 CDH1 CTNNB1 ESR1
18 11.91 CDH1 CTNNA1 CTNNB1
19 11.89 CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
20 11.86 CDH1 CTNNA1 CTNNB1
21
Show member pathways
11.78 ERBB2 ESR1 PRLR
22 11.71 CDH1 CTNNA1 CTNNB1 MUC1
23 11.59 CDH1 CTNNA1 CTNNB1
24 11.31 CDH1 CTNNA1 CTNNB1
25 11.31 CDH1 CTNNA1 CTNNB1 ERBB2
26 11.29 CTNNA1 CTNNB1
27 11.26 CDH1 CTNNA1 CTNNB1
28 11.23 CDH1 CTNNA1 CTNNB1
29 11.22 ESR1 HSP90AA1
30 11.2 CTNNA1 CTNNB1
31 11.18 CTNNA1 CTNNB1
32 11.18 ESR2 PRLR
33 11.16 CDH1 ERBB2
34 11.16 CDH1 CTNNA1 CTNNB1
35 11.14 CTNNB1 ERBB2
36 11.1 ESR1 ESR2
37 11.1 CDH1 CTNNA1 CTNNB1
38 11.07 ESR1 ESR2
39 11.04 ESR1 HSP90AA1
40 11 ESR1 ESR2
41 10.94 CDH1 CTNNA1 CTNNB1
42 10.9 CDH1 CTNNA1
43 10.55 CDH1 CTNNA1 CTNNB1
44 10.13 ESR1 ESR2

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.81 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
2 perinuclear region of cytoplasm GO:0048471 9.78 CDH1 CTNNB1 ERBB2 HSP90AA1
3 actin cytoskeleton GO:0015629 9.63 CASK CDH1 CTNNA1
4 basolateral plasma membrane GO:0016323 9.61 CASK CTNNB1 ERBB2
5 lamellipodium GO:0030027 9.58 CDH1 CTNNA1 CTNNB1
6 cell-cell junction GO:0005911 9.54 CASK CTNNA1 CTNNB1
7 cell-cell adherens junction GO:0005913 9.43 CDH1 CTNNA1 CTNNB1
8 apical junction complex GO:0043296 9.32 CDH1 CTNNB1
9 catenin complex GO:0016342 9.13 CDH1 CTNNA1 CTNNB1
10 flotillin complex GO:0016600 8.8 CDH1 CTNNA1 CTNNB1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.8 CDH1 CTNNB1 ESR1 ESR2
2 cell adhesion GO:0007155 9.78 CASK CDH1 CTNNA1 CTNNB1
3 negative regulation of apoptotic process GO:0043066 9.61 CTNNA1 CTNNB1 PRLR
4 positive regulation of protein kinase B signaling GO:0051897 9.54 ERBB2 ESR1 HSP90AA1
5 regulation of angiogenesis GO:0045765 9.52 CTNNB1 ERBB2
6 positive regulation of telomerase activity GO:0051973 9.51 CTNNB1 HSP90AA1
7 ERBB2 signaling pathway GO:0038128 9.46 ERBB2 HSP90AA1
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.43 CTNNB1 ESR1 ESR2
9 positive regulation of muscle cell differentiation GO:0051149 9.4 CTNNA1 CTNNB1
10 intracellular estrogen receptor signaling pathway GO:0030520 9.32 ESR1 ESR2
11 entry of bacterium into host cell GO:0035635 9.16 CDH1 CTNNB1
12 adherens junction organization GO:0034332 9.13 CDH1 CTNNA1 CTNNB1
13 cellular response to indole-3-methanol GO:0071681 8.8 CDH1 CTNNA1 CTNNB1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 estrogen receptor binding GO:0030331 9.48 CTNNB1 ESR1
2 disordered domain specific binding GO:0097718 9.46 CTNNB1 HSP90AA1
3 steroid binding GO:0005496 9.43 ESR1 ESR2
4 beta-catenin binding GO:0008013 9.43 CDH1 CTNNA1 ESR1
5 gamma-catenin binding GO:0045295 9.37 CDH1 CTNNA1
6 nitric-oxide synthase regulator activity GO:0030235 9.32 ESR1 HSP90AA1
7 estrogen receptor activity GO:0030284 9.16 ESR1 ESR2
8 identical protein binding GO:0042802 9.1 CDH1 CTNNA1 ERBB2 ESR1 ESR2 HSP90AA1
9 estrogen response element binding GO:0034056 8.96 ESR1 ESR2
10 protein binding GO:0005515 10.1 CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1

Sources for Lobular Neoplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....